2018 · Translational and clinical pharmacology · open access
Quantitative analysis of acetylsalicylic acid in human blood using volumetric absorptive microsampling
Kim et al.
The finding, in our words
Acetylsalicylic acid concentrations in VAMS samples decrease without a stabilising reagent, whereas whole blood samples remain stable. For decentralised diagnostics, this means stabilisers must be added to VAMS devices before analysis to ensure accurate therapeutic drug monitoring from patient-collected samples.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In lung and renal transplant recipients, VAMS sampling with LC-MS/MS quantification of mycophenolic acid and tacrolimus showed good linearity and accuracy, and with a haematocrit-adjusted conversion formula achieved clinical agreement in most samples; tacrolimus did not require haematocrit correction. The approach is virtually painless and enables richer sampling for more accurate drug exposure estimates, supporting decentralised therapeutic drug monitoring.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
An LC-MS/MS method for tamoxifen and six metabolites in VAMS was developed and validated, with water prerinsing improving recoveries and poor room temperature stability but stability for at least 100 days at minus 80 degrees Celsius. Plasma to blood ratios were used to estimate plasma equivalent concentrations, and paired VAMS and plasma samples from ten breast cancer patients showed strong correlations and good agreement on Bland-Altman analysis, supporting reliable decentralised TDM.
This study employed volumetric absorptive microsampling to collect blood samples from neonates, revealing that existing propofol pharmacokinetic models poorly predicted drug levels in this population. A newly developed meta-model provided accurate predictions, validating the use of patient-centric microsampling for therapeutic drug monitoring in preterm and term infants.
The study developed and validated a reliable HPLC-MS method for quantifying multiple tyrosine kinase inhibitors from VAMS microsamples of capillary blood, showing acceptable accuracy, precision, and 28-day stability at -21°C, with results comparable to venous plasma in 194 samples from patients with solid tumours. This enables therapeutic drug monitoring using microsamples in oncology practice.